Indian contract services provider Suven Life Sciences Ltd has been granted two product patents each in China and Russia for new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
The two product patents were granted in China (100378108 and 100378109) and Russia (2325392 and 2340619) corresponding to two of their new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
The patents are valid until 2023 and 2024 respectively, announced Suven in a press release.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
In December, Suven Life Sciences Ltd was granted two patents by the Canadian Intellectual Property Office covering the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents.
In November, Suven Life Sciences Ltd bagged three new patents by the European Patent Office for its research relating to neurodegenerative diseases.
With these new patents, Suven has total of seven granted EPO patents on NCEs. All the seven EPO patents have been validated in the 37 member countries of Europe. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various stages of clinical development like at phase-I or phase-II.
In October, Suven Life Sciences Ltd has secured product patents for SUVN-502 in nine regions. SUVN-502 is Suven Life’s experimental drug for treating cognitive defects associated with Alzheimer’s disease and schizophrenia.
Suven Life Sciences has secured product patents for SUVN-502 in countries including India, Mexico, South Africa, Singapore, New Zealand, Korea, Eurasia, Australia and Europe. SUVN-502 patent is valid till June 2023 in all these countries.
Suven Life Sciences completed its phase I trials for SUVN-502 in April 2009.
SUVN-502 is a lead compound intended for the symptomatic treatment of Alzheimer’s disease and other disorders of memory and cognition like attention deficient hyperactivity, Parkinson, Schizophrenia. Suven Life is planning to initiate the clinical Phase-II proof of concept studies for SUVN-502 during 2010. Suven Life may launch SUVN-502 in later 2013 or in early 2014.
In September, Suven Life Sciences Ltd secured two new US patents for its class of selective 5-HT compounds for the treatment of disorders associated with neurodegenerative diseases like Alzheimer’s disease, Parkinson and schizophrenia
Comments are closed for this Article !